During the past decade, Serv. di Ematologia Ist. di Ematologia ed Endocrinologia conducted 32 clinical trials. In the 10-year time frame, 32 clinical trials started and 9 clinical trials were completed, i.e. on average, 28.1% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 6 clinical trials were completed. i.e. 35.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Serv. di Ematologia Ist. di Ematologia ed Endocrinologia" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 18 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Bayer" with 4 trials sponsored, "European Institute of Oncology" with 2 trials sponsored and "Mario Negri Institute for Pharmacological Research" with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Serv. di Ematologia Ist. di Ematologia ed Endocrinologia" #1 collaborator was "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials as a collaborator, "CML Advocates Network" with 1 trials as a collaborator, "Canadian VIGOUR Centre" with 1 trials as a collaborator, "Clinical Research Technology S.r.l." with 1 trials as a collaborator and "Cromsource" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Serv. di Ematologia Ist. di Ematologia ed Endocrinologia" are "Acute Myeloid Leukemia" (5 trials), "Idiopathic Pulmonary Fibrosis" (4 trials), "Chronic Myeloid Leukemia" (3 trials), "Leukemia" (3 trials) and "Breast Cancer" (2 trials). Many other conditions were trialed in "Serv. di Ematologia Ist. di Ematologia ed Endocrinologia" in a lesser frequency.

Most popular intervention types in "Serv. di Ematologia Ist. di Ematologia ed Endocrinologia" are "Drug" (28 trials), "Other" (11 trials), "Procedure" (7 trials), "Biological" (2 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "PRM-151 (Zinpentraxin Alfa)" (2 trials), "adjuvant therapy" (2 trials), "cisplatin" (2 trials) and "mercaptopurine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Serv. di Ematologia Ist. di Ematologia ed Endocrinologia" are 48 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Serv. di Ematologia Ist. di Ematologia ed Endocrinologia". undefined are not yet recruiting, 11 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Serv. di Ematologia Ist. di Ematologia ed Endocrinologia, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Serv. di Ematologia Ist. di Ematologia ed Endocrinologia, 0 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".